查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1425126

HPV 相關疾病市場 – 2024 年至 2029 年預測

HPV Associated Disorders Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計 HPV 相關疾病市場在預測期內將以 9.65% 的複合年成長率成長。

人類乳突病毒家族有 100 多種病毒，其中 14 種會導致癌症。幾乎所有子宮頸癌病例都是由 HPV 引起的。子宮頸癌是開發中地區女性第二常見癌症，每年估計有 604 萬新病例和 3,342 萬人死亡。感染愛滋病毒的女性罹患子宮頸癌的幾率是未感染女性的六倍，而 5% 的子宮頸癌病例被認為是由愛滋病毒引起的。此外，與愛滋病毒相關的子宮頸癌對世界各地的年輕女性影響尤其嚴重。

子宮頸癌盛行率增加

世界衛生組織（WHO）情況說明書描述了一級預防措施，例如人類乳突病毒(HPV)疫苗，二級預防措施，例如癌前病變的篩檢和治療，以及三級預防措施，例如浸潤性子宮頸癌的診斷和治療。安寧療護是子宮頸癌綜合控制的重要組成部分。這些衛生當局法規有助於擴大 HPV 相關疾病市場。同樣，澳洲政府已承諾提供 580 萬美元支持世界衛生組織 (WHO) 於 2021 年 11 月宣布的消除子宮頸癌的全球努力。確實如此。全國子宮頸篩檢計畫幾乎總是敦促女性每五年進行一次 HPV 快速檢測，HPV 是一種導致子宮頸癌的常見病毒。

政府為治療 HPV 相關疾病所做的努力

世界各國政府都在致力於治療 HPV 相關疾病的各種努力。例如，為了實現 2030 年永續發展目標，印尼政府致力於減少可透過疫苗預防的疾病引起的發病率、死亡率和殘疾。衛生署已將改善國家衛生服務作為優先事項，擴大和加強衛生服務，並更加重視預防宣傳工作。實現這一目標的方法之一是將新疫苗（例如人類乳突病毒(HPV)疫苗）涵蓋國家免疫計劃。政府致力於建立一個更強大、更具創造性的體系。此外，世衛組織免疫策略諮詢專家小組 (SAGE) 將於 2023 年 4 月召開會議，審查顯示一劑方案與兩劑或三劑方案一樣有效的證據。我審查了該堆疊。

人們越來越偏好HPV 檢測

HPV 檢測優於其他篩檢技術，例如子宮頸抹片和目視醋酸檢查 (VIA)，並且可以識別需要更多治療的人。有些 HPV 檢測還需要簡單的拭子樣本，這樣女性就可以進行檢體，而無需在醫療保健提供者處進行骨盆腔檢查。許多 HPV 檢測可以整合到目前的檢測系統中，特別是因為它們是使用與 COVID-19 PCR 和 HIV 檢測相同的硬體進行的。此類技術可以幫助消除服務障礙，幫助公共衛生工作實現 70% 篩檢的目標。

醫療保健組織擴大舉措

據世界衛生組織稱，人類乳突病毒（HPV）合格檢測清單現在包括第四項檢測。大多數 HPV 感染會自行消失，但某些高風險類型可能會發展為子宮頸癌。子宮頸癌篩檢始終包括 HPV 感染檢測。世界衛生組織運行的體外診斷 (IVD)合格(PQ) 計劃評估各種測試，包括用於篩檢子宮頸癌和識別高危險 HPV 基因型的測試。 PQ 清單中新增的新偵測擴大了政府可用的高效能偵測的選擇範圍，特別是當政府、聯合國機構和其他合作夥伴依賴 WHO 專案來促進採購時。如果是這樣，您將擁有更廣泛的選擇。

人類乳突病毒(HPV)疫苗需求增加

在整個預期期間，由於 HPV 相關疾病的盛行率不斷上升，HPV 疫苗接種的需求預計將成為推動全球 HPV 相關疾病產業潛力的主要因素。二價、四價和單價疫苗是市面上可用的疫苗類型。所有三種疫苗對於預防病毒 16 和 18 都非常有效，這兩種病毒佔子宮頸癌治癒率的 70%。監管部門對新疫苗的接受度預計將增加疫苗接種和接種的機會，加速 HPV 相關疾病市場的擴張。

亞太地區骨骼發育不良市場預計將穩定成長。

預計亞太地區 HPV 相關疾病市場將受到主要 HPV 相關疾病行業參與者的存在以及該地區各種舉措的成長的推動。例如，2022 年 10 月，世界衛生組織西太平洋區域委員會第 73 屆會議的最後一天，代表團將致力於預防和控制子宮頸癌、覆蓋未覆蓋人群並核准該區域所有社區。旨在盡可能改善人們的身心健康。超過95%的子宮頸癌與高風險人類乳突病毒（HPV）感染有關。持續的 HPV 感染可導致女性罹患子宮頸癌，但大多數感染具有自限性，沒有任何症狀。根據世界衛生組織估計，2020年西太平洋地區有145,700名女性被診斷出罹患子宮頸癌，其中74,900人死於這種最可治療和避免的疾病。

HPV相關疾病診斷

  • 醋（醋酸）溶液測試：當醋溶液注射到感染HPV的生殖器時，它會變成白色。此測試對於發現難以看到的扁平病灶很有用。
  • 子宮頸抹片檢查試驗 醫生從陰道或子宮頸採集細胞樣本進行實驗室分析。
  • DNA 檢測使用從子宮頸取出的細胞來識別與生殖器惡性相關的高風險 HPV 株的 DNA。對於 30 歲以上的女性，除了子宮頸抹片檢查外，還建議進行該檢查。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 先決條件

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章 HPV相關疾病市場：依適應症分類

  • 介紹
  • CIN
  • 子宮頸癌
  • AIN
  • 肛門癌
  • 其他

第6章 HPV相關疾病市場：依治療分類

  • 介紹
  • 預防
  • 治療

第7章 HPV相關疾病市場：依通路分類

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 HPV相關疾病市場：依地區分類

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第10章 公司簡介

  • Merck Vaccines
  • PapiVax Biotech
  • Cleveland Clinic
  • Johns Hopkins Medicine
  • Advaxis
  • Kovina Therapeutics
  • Gavi
  • The Native Antigen Company
  • Eurogin
  • Queensland Health
簡介目錄
Product Code: KSI061616221

The HPV associated disorders market is estimated to grow at a CAGR of 9.65% during the forecast period.

More than 100 viruses make up the human papillomavirus family, 14 of which can lead to cancer. HPV is the reason for almost all occurrences of cervical cancer. In women living in less developed areas, cervical cancer is the second most prevalent kind, with an estimated 6,04,000 new cases and 3342,000 deaths every year. Cervical cancer is six times more common in women living with HIV than in those without the virus, and HIV is thought to be the cause of 5% of cervical cancer occurrences. Furthermore, younger women are disproportionately affected by HIV-related cervical cancer in all parts of the world.

Growing prevalence of cervical cancer

The World Health Organization (WHO) Factsheet states that palliative care is a crucial component of comprehensive cervical cancer control, in addition to primary prevention measures like HPV vaccination, secondary prevention measures like pre-cancerous lesion screening and treatment, and tertiary prevention measures like diagnosis and treatment of invasive cervical cancer. Such health authority rules contribute to the HPV-associated disorders market expansion. Similar to this, the Australian Government has pledged USD 5.8 million to assist the World Health Organization's (WHO) announcement of a worldwide commitment to eradicate cervical cancer in November 2021. The National Cervical Screening Program urges women to have a fast test for HPV, a common virus that nearly invariably leads to cervical cancer, every five years.

Government initiatives for the treatment of HPV Associated Disorders

Government around the globe is focusing on various initiatives for the treatment of HPV-associated disorders. For instance, to meet the 2030 SDGs, the Indonesian government is dedicated to reducing morbidity, mortality, and disability brought on by illnesses that may be prevented by vaccination. The Ministry of Health has made it a priority to improve health services in the nation by expanding and strengthening health services to concentrate more on preventive promotive efforts. One way to achieve this is by adding new vaccines to the national immunisation programme, such as the HPV vaccine. The government is dedicated to creating a more robust and inventive system. Furthermore, the WHO Strategic Advisory Group of Experts on Immunisation (SAGE) met in April 2023 and reviewed the mounting evidence showing single-dose schedules are just as effective as two- or three-dose regimens.

Growing preference for HPV tests

HPV tests outperform other screening techniques, such as pap smears and visual inspection with acetic acid (VIA), allowing for the identification of more people who require treatment, due to the greater quality, patients who obtain a negative HPV test result can frequently wait longer between tests, which is advantageous for both them and the healthcare system. A few HPV tests even provide patients the option to collect their sample with a simple swab, giving women the option to get tested without having a healthcare provider do a pelvic exam. Numerous HPV tests are even performed using the same hardware as COVID-19 PCR and HIV assays, among others, allowing them to be integrated into current laboratory systems. Such technologies can help remove more obstacles to services and make it easier for public health initiatives to reach the aim of 70% screening.

Growing initiatives by healthcare organizations

The list of prequalified tests for human papillomavirus (HPV) now includes a fourth test, according to WHO. While the majority of HPV infections go away on their own, some high-risk varieties can result in cervical cancer. Cervical cancer screening always includes testing for HPV infection. The prequalification (PQ) programme for in vitro diagnostics (IVDs) run by the WHO assesses a variety of tests, including those used to screen for cervical cancer and identify high-risk HPV genotypes. The inclusion of yet another item to the PQ list broadens the selection of high-performance tests that nations may access, especially when governments, UN organisations, or other partners depend on the WHO programme to facilitate their purchase.

Rising demand for HPV vaccinations

Throughout the anticipated period, the demand for HPV vaccinations is anticipated to be the main factor driving the global HPV-associated disorders industry potential due to the rising prevalence of HPV-related disorders. Bivalent, quadrivalent, and nonavalent vaccinations are the kinds of vaccinations available on the market. The three vaccinations are all quite effective at protecting against the 16 and 18 viruses, which represent 70% of cervical cancer cures. The regulatory authorities' acceptance of the new vaccine increases the accessibility of vaccines for immunisation or vaccination, which is projected to hasten HPV-associated disorders market expansion.

Skeletal dysplasia market in the Asia Pacific region is anticipated to grow steadily.

The HPV-associated disorders market in the Asia Pacific is anticipated to be fueled by the presence of major HPV-associated disorders industry players and growth in various initiatives in the region. For instance, in October 2022, on the last day of the 73rd session of the WHO Regional Committee for the Western Pacific, delegates approved frameworks designed to prevent and control cervical cancer, reach the unreached, and advance the best possible mental and physical health for everyone in the region. Over 95% of occurrences of cervical cancer are associated with high-risk human papillomavirus (HPV) infection. Persistent HPV infections can lead to cervical cancer in women, even though the majority of infections clear up on their own and have no symptoms. According to estimates by WHO, 145,700 women in the Western Pacific Region received a cervical cancer diagnosis in 2020, and 74,900 of them lost their lives to the most treatable and avoidable illness.

HPV Associated Disorders Diagnosis

  • Vinegar (acetic acid) solution test, genital regions infected with HPV become white when a vinegar solution is administered to them. This test is useful in locating flat lesions that are hard to spot.
  • Pap Test, for laboratory analysis, the doctor takes a sample of cells from your vagina or cervix. Pap testing can identify irregularities that may result in cancer.
  • DNA Tests can identify the DNA of high-risk HPV strains that have been connected to genital malignancies using cells taken from the cervix. For women 30 years of age and above, it is advised in addition to the Pap test.

Market Key Developments

  • In April 2023, a Phase 2 clinical study was initiated by KinoPharma, Inc. and IWAKI SEIYAKU CO., LTD. to verify the effectiveness of a therapeutic candidate for the treatment of cutaneous warts in humans.
  • In December 2021, a one-year follow-up of safety and efficacy data in participants from REVEAL1, the completion of REVEAL2 enrollment, and the advancement of its pre-treatment biomarker candidate for VGX-3100 to be further developed with QIAGEN were among the updates on the Phase 3 programme for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL) that INOVIO released.

Segmentation:

By Indication

  • CIN
  • Cervical Cancer
  • AIN
  • Anal Cancer
  • Others

By Therapy

  • Prevention
  • Treatment

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. HPV ASSOCIATED DISORDERS MARKET BY INDICATION

  • 5.1. Introduction
  • 5.2. CIN
  • 5.3. Cervical Cancer
  • 5.4. AIN
  • 5.5. Anal Cancer
  • 5.6. Others

6. HPV ASSOCIATED DISORDERS MARKET BY THERAPY

  • 6.1. Introduction
  • 6.2. Prevention
  • 6.3. Treatment

7. HPV ASSOCIATED DISORDERS MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies
  • 7.4. Online Pharmacies

8. HPV ASSOCIATED DISORDERS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Merck Vaccines
  • 10.2. PapiVax Biotech
  • 10.3. Cleveland Clinic
  • 10.4. Johns Hopkins Medicine
  • 10.5. Advaxis
  • 10.6. Kovina Therapeutics
  • 10.7. Gavi
  • 10.8. The Native Antigen Company
  • 10.9. Eurogin
  • 10.10. Queensland Health